<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134169</url>
  </required_header>
  <id_info>
    <org_study_id>K0202-E</org_study_id>
    <nct_id>NCT04134169</nct_id>
  </id_info>
  <brief_title>Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)</brief_title>
  <official_title>A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis : 5-year Results From the K0202 Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of
      FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis: 5-year Results
      From the K0202 Extension Study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">August 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>5 years</time_frame>
    <description>(Rate of Adverse Event, Number of Participants with Adverse Event)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in DAS(Disease activity scores)28-ESR from baseline</measure>
    <time_frame>5 years</time_frame>
    <description>DAS range is from ≥ 3.2 (inactive) , ＞3.2 but ≤ 5.1(moderate), ＞5.1(very active)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in KHAQ(Korean Health assessment questionnaire) from baseline</measure>
    <time_frame>5 years</time_frame>
    <description>KHAQ range is from 0 (clear) to 60 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CDAI (clinical disease activity index) from baseline</measure>
    <time_frame>5 years</time_frame>
    <description>CDAI range is from 0 (clear) to 76 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in 100mm Pain VAS(Visual analogue scale) from baseline</measure>
    <time_frame>5 years</time_frame>
    <description>100mm Pain VAS range is from 0 (clear) to 100 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Modified Sharp/Van der Heijde Socre from baseline</measure>
    <time_frame>5 years</time_frame>
    <description>Modified Sharp/Van der Heijde Socre range is from 0 (clear) to 448 (severe)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable(observational study)</intervention_name>
    <description>Not applicable(observational study)</description>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Moderate to Severe Rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who enrolled K0202 Clinical Trial(parent study) and has been given more than
             one medication.

          2. Subjects who understand and voluntarily sign an informed consent form

        Exclusion Criteria:

        1. Any other condition which the investigator judges would make patient unsuitable for
        study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae Hun Jung</last_name>
    <phone>+82-2-20367615</phone>
    <email>jhjung@kangstem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-hyang Woo</last_name>
    <email>jhwoo@kangstem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul national University Boramae medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanghui Kim</last_name>
      <phone>+82-2-8703969</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

